Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6800970 | Journal of Psychiatric Research | 2014 | 9 Pages |
Abstract
Plasma APP derivative analysis holds promise as a potential biomarker for use in ASD targeted treatment. Reduction in sAPP (total) and sAPPα may be a novel pharmacodynamic property of acamprosate. Future study is required to address limitations of the current study to determine if baseline APP derivative analysis may predict subgroups of persons with idiopathic or FXS-associated ASD who may respond best to acamprosate or to potentially other modulators of glutamate and/or GABA neurotransmission.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Craig A. Erickson, Balmiki Ray, Bryan Maloney, Logan K. Wink, Katherine Bowers, Tori L. Schaefer, Christopher J. McDougle, Deborah K. Sokol, Debomoy K. Lahiri,